NASDAQ : VERU
Veru Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 37.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 37.34M |
| Enterprise Value | 14.29M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 17.05M |
| Shares Outstanding | 17.05M |
| Shares Change (YoY) | +38.32% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 9.22% |
| Owned by Institutions (%) | 14.55% |
| Float | 15.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.42 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -64.54% |
| Return on Assets (ROA) | -54.03% |
| Return on Invested Capital (ROIC) | -453.18% |
| Return on Capital Employed (ROCE) | -90.10% |
| Weighted Average Cost of Capital (WACC) | -2.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$680,428 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.20 |
| 52-Week Price Change | -37.43% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 2.50 |
| Relative Strength Index (RSI) | 40.26 |
| Average Volume (20 Days) | 218,755 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.47M |
| Short Previous Month | 1.40M |
| Short % of Shares Out | 8.60% |
| Short % of Float | 9.47% |
| Short Ratio (days to cover) | 7.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.82M |
| Pretax Income | -14.11M |
| Net Income | -13.61M |
| EBITDA | -27.70M |
| EBIT | -27.82M |
| Earnings Per Share (EPS) | -$0.67 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 25.74M |
| Total Debt | 2.68M |
| Net Cash | 23.05M |
| Net Cash Per Share | $1.35 |
| Equity (Book Value) | 28.38M |
| Book Value Per Share | 1.66 |
| Working Capital | 21.07M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -26.04M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 113,154 |
| Net Borrowing | n/a |
| Free Cash Flow | -26.04M |
| FCF Per Share | -$1.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.32% |
| Shareholder Yield | -38.32% |
| Earnings Yield | -30.67% |
| FCF Yield | -69.75% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.67 |
| Price Target Difference | 1,072.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |